A meeting with 48 opinion leaders, research experts and clinicians on Duchenne muscular dystrophy (DMD) bone biology from Canada and USA (15 states/provinces) was held in Bethesda, Maryland, USA from May 12 to May 13, 2016 to discuss the way forward in the research and management of bone health in DMD. The devastating effects of dystrophin loss in DMD have been the focus of both basic and clinical research for decades. However, less attention has been given to the effects of DMD and that of the major therapy for DMD, glucocorticoids (GC), on bone health.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...